James Watters
0009-0005-3116-5929
Publication & Citation Trends
Publications
0 total
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations OA
Cited by 72
Semantic Scholar
Abstract P5-16-10: RLY-2608: The first allosteric mutant- and isoform-selective inhibitor of PI3Kα, is efficacious as a single agent and drives regressions in combination with standard of care therapies in PIK3CA mutant breast cancer models
Cited by 1
Semantic Scholar
Abstract 1455: RLY-4008, a novel precision therapy for FGFR2-driven cancers designed to potently and selectively inhibit FGFR2 and FGFR2 resistance mutations
Cited by 13
Semantic Scholar
Abstract P251: Discovery and characterization of RLY-2608: The first allosteric, mutant, and isoform-selective inhibitor of PI3Kα
Cited by 4
Semantic Scholar
Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers OA
Cited by 34
Semantic Scholar
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma OA
Cited by 85
Semantic Scholar
TP53 mutations emerge in circulating cell-free DNA obtained from patients undergoing treatment with the HDM2 antagonist SAR405838.
Cited by 6
Semantic Scholar
303 A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumors
Cited by 3
Semantic Scholar
Research Topics
Fibroblast Growth Factor Research
(108)
Eosinophilic Disorders and Syndromes
(78)
PI3K/AKT/mTOR signaling in cancer
(58)
Lung Cancer Treatments and Mutations
(41)
Advanced Breast Cancer Therapies
(17)
Affiliations
Universidad San Pablo CEU
Merck & Co., Inc., Rahway, NJ, USA (United States)
University College Hospital
Howard Hughes Medical Institute
Harvard University